

1 **Running title**

2 SARS-CoV-2 Infection and Seropositivity among Pets of Persons with Laboratory-Confirmed SARS-
3 CoV-2, 2020

4 **Keywords**

5 SARS-CoV-2, COVID-19, Coronavirus, pets, dog, cat, zoonoses, One Health

6 **Title**

7 One Health Investigation of SARS-CoV-2 Infection and Seropositivity among Pets in Households with
8 Confirmed Human COVID-19 Cases — Utah and Wisconsin, 2020

9 **Authors**

10 Grace W. Goryoka¹, Caitlin M. Cossaboom¹, Radhika Gharpure¹, Patrick Dawson¹, Cassandra Tansey¹,
11 John Rossow¹, Victoria Mrotz¹, Jane Rooney², Mia Torchetti³, Christina M. Loiacono³, Mary L.
12 Killian³, Melinda Jenkins-Moore³, Ailam Lim⁴, Keith Poulsen⁴, Dan Christensen⁴, Emma Sweet⁴, Dallin
13 Peterson⁵, Anna L. Sangster⁵, Erin L. Young⁵, Kelly F. Oakeson⁵, Dean Taylor⁶, Amanda Price⁶, Tair
14 Kiphibane⁷, Rachel Klos⁸, Darlene Konkle⁹, Sanjib Bhattacharyya¹⁰, Trivikram Dasu¹⁰, Victoria T.
15 Chu¹, Nathaniel M. Lewis¹, Krista Queen¹, Jing Zhang¹, Anna Uehara¹, Elizabeth A. Dietrich¹, Suxiang
16 Tong¹, Hannah L. Kirking¹, Jeffrey R. Doty¹, Laura S. Murrell¹, Jessica R. Spengler¹, Anne Straily¹,
17 Ryan Wallace¹, Casey Barton Behravesh¹

18 **Author Affiliations**

19 ¹Centers for Disease Control and Prevention, Atlanta, Georgia (G. Goryoka, C. Cossaboom, R.
20 Gharpure, P. Dawson, J. Rossow, C. Tansey, V. Mrotz, V. Chu, N. Lewis, K. Queen, J. Zhang, A.
21 Uehara, E. Dietrich, S. Tong, H. Kirking, J. Doty, L. Murrell, J. Spengler, A. Straily, R. Wallace, C.
22 Barton Behravesh)

23 ²United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary
24 Services, Fort Collins, CO (J. Rooney)

25 ³United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary
26 Services, National Veterinary Services Laboratories, Ames, IA (M. Torchetti, C. Loiacono, M. Killian,
27 M. Jenkins-Moore)

28 ⁴Wisconsin Veterinary Diagnostic Laboratory, Madison, Wisconsin, USA (A. Lim, K. Poulsen, D.
29 Christensen, E. Sweet)

30 ⁵Utah Department of Health, Salt Lake City, Utah, USA (D. Peterson, A. Sangster, E. Young, K.
31 Oakeson)

32 ⁶Utah Department of Agriculture and Food, Salt Lake City, Utah, USA (D. Taylor, A. Price)

33 ⁷Salt Lake County Health Department, Salt Lake City, Utah, USA (T. Kiphibane)

34 ⁸Wisconsin Department of Health Services, Madison, Wisconsin, USA (R. Klos)

35 ⁹Wisconsin Department of Agriculture, Trade and Consumer Protection, Madison, Wisconsin, USA (D.
36 Konkle)

37 ¹⁰City of Milwaukee Health Department Milwaukee, Wisconsin, USA (S. Bhattacharyya, T. Dasu)

38 **Corresponding author**

39 Grace W. Goryoka, 1600 Clifton Rd, MS H16-5; Atlanta, Georgia, 30033; Phone: +1 (404) 718-3466;

40 Fax: +1 (404) 718-1900; E-mail: GGoryoka@cdc.gov

41

42 **Abstract**

43 *Background*

44 Approximately 67% of U.S. households have pets. Limited data are available on SARS-CoV-2 in pets.
45 We assessed SARS-CoV-2 infection in pet cohabitants as a sub-study of an ongoing COVID-19
46 household transmission investigation.

47 *Methods*

48 Mammalian pets from households with ≥ 1 person with laboratory-confirmed COVID-19 were eligible
49 for inclusion from April–May 2020. Demographic/exposure information, oropharyngeal, nasal, rectal,
50 and fur swabs, feces, and blood were collected from enrolled pets and tested by rRT-PCR and virus
51 neutralization assays.

52 *Findings*

53 We enrolled 37 dogs and 19 cats from 34 of 41 eligible households. All oropharyngeal, nasal, and rectal
54 swabs tested negative by rRT-PCR; one dog's fur swabs (2%) tested positive by rRT-PCR at the first
55 animal sampling. Among 47 pets with serological results from 30 households, eight (17%) pets (4 dogs,
56 4 cats) from 6 (20%) households had detectable SARS-CoV-2 neutralizing antibodies. In households
57 with a seropositive pet, the proportion of people with laboratory-confirmed COVID-19 was greater
58 (median 79%; range: 40–100%) compared to households with no seropositive pet (median 37%; range:
59 13–100%) ($p=0.01$). Thirty-three pets with serologic results had frequent daily contact (≥ 1 hour) with
60 the human index patient before the person's COVID-19 diagnosis. Of these 33 pets, 14 (42%) had
61 decreased contact with the human index patient after diagnosis and none (0%) were seropositive; of the
62 19 (58%) pets with continued contact, 4 (21%) were seropositive.

63 *Interpretations*

64 Seropositive pets likely acquired infection from humans, which may occur more frequently than
65 previously recognized. People with COVID-19 should restrict contact with animals.

66 *Funding*

67 Centers for Disease Control and Prevention, U.S. Department of Agriculture

68 **Introduction**

69 SARS-CoV-2, the cause of the coronavirus disease 2019 (COVID-19) pandemic, likely originated in
70 bats.¹ Threats from pathogens shared by humans and animals highlight the need for a One Health
71 approach for detection, prevention, and control.² One Health is a collaborative, multisectoral, and
72 transdisciplinary approach with the goal of achieving optimal health outcomes recognizing the
73 interconnection between people, animals, plants, and their shared environment.

74 In the United States (U.S.), approximately 85 million households (67%) own ≥ 1 pet, with dogs (63
75 million households) and cats (43 million households) being most popular.³ Human-animal interactions
76 are associated with improved mental, social, and physiologic health⁴ and are critical for people with
77 service and working animals⁵.

78 Some animals, including pets, have been naturally infected with SARS-CoV-2, almost exclusively after
79 exposure to an infected person.⁶⁻⁸ Dogs, cats, ferrets, hamsters, and rabbits are pet species with
80 demonstrated susceptibility to SARS-CoV-2 infection under experimental conditions. Cats, ferrets, and
81 hamsters can transmit the virus to naïve cohabitants of the same species.⁹⁻¹⁴ Additionally, no virus,
82 including SARS-CoV-2, has ever been reported as a contaminant on pet fur. However, animal health and
83 welfare concerns have been reported,^{15,16} including reports of misuse of cleaning products on pets to the
84 Pet Poison Hotline (R. Schmid, personal communication).

85 We conducted a One Health household transmission investigation to better characterize SARS-CoV-2
86 infection in mammalian pets living in households with people with COVID-19 to inform guidance and
87 decision-making during this pandemic and for future preparedness efforts.

88 **Research in context**

89 *Evidence before this study*

90 Both natural and experimental infections with SARS-CoV-2 have been reported in multiple species of
91 companion animals, including dogs, cats, ferrets, hamsters, and rabbits. Cats, ferrets, and hamsters can
92 transmit SARS-CoV-2 to naïve members of the same species. Natural infections of companion animals
93 have occurred almost exclusively after contact with a person with COVID-19.

94 *Added value of this study*

95 This is one of the earliest studies to assess risk and behavioral factors related to SARS-CoV-2
96 transmission between people and pets. In households with humans with laboratory-confirmed COVID-
97 19 and pets, 20% had pets with serological evidence of past SARS-CoV-2 infection. SARS-CoV-2
98 seropositivity in pets was more prevalent among households with higher rate of human COVID-19
99 infections, and less prevalent among households where owners limited interactions with pets when the
100 owner's COVID-19 symptoms began. To our knowledge, this is the first study to detect RNA of SARS-
101 CoV-2, or any virus, on animal fur.

102 *Implications of all the available evidence*

103 Understanding the epidemiologic role that animals may play in the COVID-19 pandemic is crucial to
104 inform guidance and decision making for public health and animal health officials. Our findings add to
105 the growing body of evidence demonstrating SARS-CoV-2 transmission can occur between people and
106 pets—most often from people to pets—and suggest this transmission may occur more frequently than
107 previously recognized. These data highlight the importance of further research, including identification
108 of specific risk factors for human-to-pet transmission, addressing pets in public health guidance during
109 pandemics, and including pets in future pandemic preparedness planning.

110 **Methods**

111 *Participant Enrollment*

112 The U.S. Centers for Disease Control and Prevention (CDC) collaborated with local and state public
113 health and agriculture departments in Utah and Wisconsin, Wisconsin Veterinary Diagnostic Laboratory

114 (WVDL), and USDA to conduct a One Health investigation that enrolled mammalian pets from an
115 ongoing COVID-19 household transmission investigation that included households with ≥ 1 person with
116 laboratory-confirmed COVID-19 captured by public health surveillance, previously described.¹⁷ Human
117 household members with nasopharyngeal or nasal swabs positive by real-time reverse-transcription
118 polymerase chain reaction (rRT-PCR) or who had SARS-CoV-2 antibodies were classified as having
119 laboratory-confirmed COVID-19¹⁷; additionally, human household patients reporting any symptoms
120 since illness onset of the index case were considered symptomatic. The investigation enrolled human
121 index COVID-19 patients (hereafter addressed as index patients) and household contacts in March 2020
122 from 62 households to determine secondary household infection rates over a 14-day follow up period
123 since household enrollment. Detailed epidemiologic, clinical, and exposure information was collected
124 for all human household members; most human household members had respiratory specimens collected
125 for SARS-CoV-2 viral testing and blood for serology testing at ≥ 2 time points. Physical characteristics
126 of each residence, including size, were also described.¹⁷

127 Of 62 enrolled households, 41 households with ≥ 1 mammalian pet living in the household were eligible
128 for inclusion in this One Health investigation (Figure S1). Eligible households were contacted by phone
129 during March–April 2020. Pets were enrolled if owners consented, a questionnaire was completed, and
130 ≥ 1 sample was collected from each pet. Phone interviews were conducted prior to initial home visits to
131 identify pet species residing in the home and whether the pet(s) developed clinical signs consistent with
132 SARS-CoV-2 infection after the index patient’s COVID-19 diagnosis.

133 *Household Visits*

134 Initial household visits for pet sampling occurred between April–May 2020 after enrollment in this
135 investigation. Pet sampling was conducted in coordination with repeat visits for the human investigation
136 where possible. During the first household visit for pet sampling, CDC field teams administered a
137 questionnaire (Supplementary Material 1) to capture information on each pet’s demographics, past

138 medical history, household knowledge of public health recommendations, and the following variables
139 for the pet after the index patient's illness onset: clinical signs; household and community interactions;
140 and household and personal precautionary measures taken. Households were also given an educational
141 information sheet on animals and SARS-CoV-2 (Supplementary Material 2).
142 During household visits, veterinarians attempted to collect oropharyngeal, nasal, rectal, and fur swabs,
143 feces, and blood from pets. Bilateral deep nasal, oropharyngeal, and rectal swabs were collected, when
144 possible, using sterile polyester tipped swabs (tip diameter, 1.981 mm for nasal, 5.2 mm for oral and
145 rectal). Swabs were placed into 3mL of brain heart infusion broth. Fur swabs were collected in duplicate
146 using 2x2-inch sterile gauze pads rubbed across the back and the abdomen, as well as the dorsal and
147 ventral paws and between the metacarpal and digital pads of each pet. One sample was stored dry and
148 one was stored in RNAlater (Thermo Fisher Scientific, Waltham, Massachusetts). All samples, except
149 for dry fur swabs and fecal samples, were stored on ice packs for immediate shipping and were
150 processed for testing upon arrival at WVDL (Madison, Wisconsin). Dry fur swabs and fecal samples
151 were placed in containers without media and were frozen immediately at -80°C until testing. Serum
152 samples were obtained from venous blood (1–3mL) collected and processed in serum separator tubes;
153 sera were decanted and stored at -80°C until testing.

154 *rRT-PCR and Serology of Animal Specimens*

155 Preliminary RNA extraction and rRT-PCR testing of animal specimens occurred at WVDL
156 (Supplementary Methods). If rRT-PCR was positive at WVDL for either target, the sample was
157 considered a presumptive positive and sent to the national animal reference laboratory, USDA's
158 National Veterinary Services Laboratories (NVSL; Ames, Iowa) for confirmatory testing per the USDA
159 Case Definition ([https://www.aphis.usda.gov/animal_health/one_health/downloads/SARS-CoV-2-case-](https://www.aphis.usda.gov/animal_health/one_health/downloads/SARS-CoV-2-case-definition.pdf)
160 [definition.pdf](https://www.aphis.usda.gov/animal_health/one_health/downloads/SARS-CoV-2-case-definition.pdf)). One dry fur swab, the duplicate of the positive fur swab stored in RNAlater, was
161 forwarded to NVSL for confirmatory testing, including rRT-PCR, sequencing, and viral culture attempts

162 (Supplementary Methods). The positive fur swab stored in RNAlater was forwarded to CDC to attempt
163 sequencing (Supplementary Methods). Serum neutralizing antibodies were assessed at NVSL by a
164 SARS-CoV-2 virus neutralization (VN) assay (Supplementary Methods). Neutralizing titers of 1:8–1:16
165 were considered suspect in the absence of other positive findings; titers > 1:16 were considered
166 seropositive.

167 *Analysis*

168 Characteristics of enrolled pets, risk factors for seropositivity, number of human cases and household
169 infection rates, and clinical features of human cases within households were analyzed using SAS version
170 9.4 (SAS Institute, Cary NC). Clopper-Pearson (exact) method was used to calculate 95% confidence
171 intervals for seropositivity rates. Frequent daily contact was defined as having a duration of interaction
172 >1 hour/day between the index patient and the pet (range:1→12 hours). Features of households with and
173 without seropositive pets were compared using Mann-Whitney-Wilcoxon tests.

174 *Role of the Funding Source*

175 CDC and USDA provided funding for this investigation. All coauthors had access to all data and had
176 final responsibility to submit for publication. This activity was reviewed by CDC and was conducted
177 consistent with applicable federal law and CDC policy.

178 **Results**

179 Initial household visits for pet sampling occurred from 0–32 days (median: 14 days) after enrollment in
180 the household transmission investigation. Fifty-six pets (37 dogs, 19 cats) from 34 of 41 eligible (83%)
181 households were enrolled (Figure S1; Table 1); 21 households had only dog(s), seven households had
182 only cat(s), and six households had dogs and cats. Median household size was 4 people (range: 2–8) and
183 1 pet (range: 1–5) (Table 2). The median proportion of human household members with laboratory-
184 confirmed COVID-19 was 45% (range: 13%–100%); of 72 total people with confirmed infection, 71
185 (99%) ever experienced symptoms. Additional household characteristics are described in Table 2.

186 Fifty-six pets (100%) had oral and fur swabs, 55 (98%) had nasal swabs, 54 (96%) had rectal swabs, 14
187 (25%) provided fecal samples, and 47 (84%) provided blood samples. Fourteen pets had repeat oral,
188 nasal, rectal, and fur swabs, 6 had repeat fecal samples, and 11 had repeat blood samples.

189 The median time from symptom onset of the index patient to first date of pet sampling was 27 days
190 (range: 3–46 days; Table 2). The median time from first positive diagnostic result of the index patient to
191 first date of pet sampling was 20.5 days (range: 3–42 days) and was similar between households with
192 and without seropositive pets (21.5 vs. 20 days).

193 All oropharyngeal, nasal, and rectal swabs and fecal specimens tested negative by rRT-PCR, except one
194 rectal swab sample from a cat was presumptive positive that was not confirmed (Supplementary
195 Materials; Table S1). Among 47 pets with serological results from 30 households, eight pets (17%; 4
196 dogs, 4 cats) from 6 (20%) households, had detectable SARS-CoV-2 neutralizing antibodies. Three pets
197 from these 6 households had seronegative results. The neutralizing titers for all seropositive dog samples
198 were 32 while cat titers ranged from 32 to 128 (Table S1). Demographic pet data by serology result are
199 presented in Table 1. Timelines for human and animal sample collection among households with
200 seropositive pets, as well as symptom onset and duration in people in those households, are depicted in
201 **Figure 1.**

202 SARS-CoV-2 RNA was detected from duplicate fur swabs from one of 56 pets (2%) at the first pet
203 sampling visit and subsequent fur swabs from this dog were negative (Figure 2). The day the positive fur
204 swab was collected, all six human household members reported symptoms consistent with COVID-19.
205 Five people had nasopharyngeal swabs collected on that day, and four were positive by rRT-PCR. The
206 person who was initially not tested and the one who was initially negative were tested two days later,
207 both were positive. (Figure 2). Seven near-complete or complete-genomes were generated from this
208 household; one each from humans 1–3, three from human 4 collected at three time-points, and one
209 consensus sequence from the dog fur swabs. High sequence similarity suggests one introduction from

210 the community and subsequent internal household transmission (Figure 2; Figure S2). Notably, the dog
211 had no evidence of infection; all samples were negative by rRT-PCR and the dog was also seronegative
212 (Figure 2). Viral culture was attempted on the rRT-PCR positive fur swab, but was negative.

213 Owners reported clinical signs consistent with SARS-CoV-2 infection among 14 (25%) pets during the
214 time from symptom onset of the index patient until time of sampling (Table S2). The most reported
215 clinical signs were respiratory (16%), including sneezing (7%), coughing (7%) and nasal discharge
216 (5%). Among the 8 seropositive pets, clinical signs were reported in only 2 (25%); one dog had nasal
217 discharge and one dog had decreased appetite. Among 39 seronegative pets, clinical signs were reported
218 in 8 (21%) (Table S2).

219 Forty-six (98%) of 47 pets with serological results were primarily indoor pets; one pet, an 8-year-old
220 seropositive cat, spent $\geq 50\%$ time outdoors (Table 1). Seropositivity among pets occurred more
221 commonly among households with higher rates of secondary transmission among people; the median
222 proportion of people with laboratory-confirmed COVID-19 in households with a seropositive pet was
223 79% (range: 40–100%) compared to 37% in households with no seropositive pet (range: 13–100%)
224 ($p=0.01$) (Table 2). Overall, owners reported pets had fewer daily interactions lasting ≥ 1 hour and fewer
225 types of interaction with the index patient after their COVID-19 diagnosis; interactions included petting,
226 cuddling, feeding, sleeping in the same location, pets licking the index patient's face or hands, taking for
227 walks, sharing food, and grooming (Figure 3). Among the 47 pets with serologic results, 33 (70%) pets
228 were reported to have frequent daily contact (≥ 1 hour) with the index patient before the person's
229 diagnosis. Of 14 pets with decreased interactions, none (0%) were seropositive. Nineteen pets continued
230 to have frequent contact with the index patient after their diagnosis; of these, 4 (21%) were seropositive.

231 Five (15%) of 34 households, comprising 12 (21%) pets, reported that, after their COVID-19 diagnosis,
232 the index patient began wearing face masks and 2 (6%) also reported glove use around pets. In

233 households using face masks, among pets with serological results, one of eight (13%) pets was
234 seropositive, while in households not using face masks, seven of 39 (18%) pets were seropositive.
235 Of 34 households, 10 (29%) identified a household member familiar with CDC recommendations for
236 people with suspected or confirmed COVID-19 restricting contact with pets¹⁸; three (30%) of the 10
237 households had a seropositive pet. Of the 10 households familiar with CDC recommendations,
238 implementation of precautions was low; the index patient in one (10%) household reduced interactions
239 with pets after the person's diagnosis, one (10%) household used masks and gloves while interacting
240 with pets, and one (10%) household reported both reduced interaction and mask and glove use.

241 **Discussion**

242 The epidemiologic role of pets in the COVID-19 pandemic is not fully understood. This One Health
243 investigation systematically evaluated pets residing in households with people with laboratory-
244 confirmed COVID-19. At the time this investigation began, three countries had reported natural SARS-
245 CoV-2 infection in 11 animals, including household pets.^{8,19,20} This investigation identified a higher rate
246 of seropositivity (17%) across enrolled pets with serological results living in households with human
247 COVID-19 cases compared to previously published studies.^{7,21,22} The 12% seropositivity rate in dogs
248 with serological results in our investigation was similar to a previous study²²; however, the 31%
249 seropositivity in cats is higher than previous reports that range from 0-15% seropositivity.^{7,22,23}
250 While 25% of pets were reported to have clinical signs consistent with SARS-CoV-2 infection, no
251 animals received veterinary treatment specific to these signs. Only two seropositive animals identified
252 were reported to have mild clinical signs consistent with SARS-CoV-2 infection during the period when
253 the infection was most likely. Clinical signs consistent with SARS-CoV-2 infection in animals are
254 generally non-specific and could potentially be attributed to other factors. Cross-species zoonotic
255 transmission events are documented, but are likely under-recognized because of asymptomatic pet
256 infections, small sample sizes, and few published studies with variable results.^{21,22}

257 In our investigation, more seropositive pets were found in households with a greater rate of human
258 household secondary transmission. Further investigations are needed to evaluate SARS-CoV-2
259 transmission dynamics between people and pets including anthropogenic or mechanical factors such as
260 whether isolation precautions were taken or infectious dose was altered by differences in viral shedding;
261 architectural differences among homes; ventilation system usage patterns affecting air flow;
262 environmental cleaning; or personal protective equipment use. Analysis of household prevention
263 measures, such as facemask use by index patients, was limited by small sample sizes in this study;
264 further investigations are needed to characterize the effectiveness of these measures to prevent SARS-
265 CoV-2 transmission to pets.

266 Several seropositive animals identified roamed freely in the yard or neighborhood during their likely
267 infectious window, which raises concern for potential transmission of virus from infected pets to people
268 and susceptible animals, which is biologically plausible, but has not yet been documented. One
269 seropositive cat spent $\geq 50\%$ of its time outdoors. Experimental studies have documented that cats with
270 SARS-CoV-2 can transmit SARS-CoV-2 to other cats,^{13,24} leading to concerns of transmission between
271 cats that roam outdoors; however, this was not assessed in this investigation.

272 We detected SARS-CoV-2 RNA in fur swabs collected from only one dog but were not able to culture
273 the virus from these samples. Thirty (54%) pets were sampled at a time when at least one household
274 member was symptomatic and 14 (25%) pets at a time when at least one household member tested
275 positive; therefore, some environmental contamination from human viral shedding may have been
276 missed. Our findings suggest that viral RNA on the fur was due to environmental contamination from
277 human household members. Fomite transmission from pet fur seems unlikely although more studies are
278 needed to determine the potential of pet fur to serve as a fomite for SARS-CoV-2 transmission.

279 In households where the index patient decreased duration of interaction with pets after the person's
280 diagnosis, no pets in this study were seropositive. In two households with seropositive pets, the index

281 patient increased their duration of interaction with pets after their diagnosis (Figure 3). This finding
282 highlights the importance of people with suspected or confirmed COVID-19 restricting contact with pets
283 and other animals to prevent person-to-animal transmission, in accordance with CDC
284 recommendations²⁵.

285 We identified 10 households with awareness of CDC's recommendations of restricting interactions with
286 pets for people with COVID-19²⁵ before enrollment. While this metric was captured only at a single
287 time point, it emphasizes the importance of providing accurate and timely health protection messaging
288 for pets during a pandemic caused by an emerging zoonotic disease.

289 Our findings provide additional characterization of potential SARS-CoV-2 transmission from people
290 with laboratory-confirmed COVID-19 to pets in households; however, several limitations are noted.
291 While directionality cannot be proven based on these results, the epidemiological information gathered,
292 in conjunction with what is currently known about disease course and shedding of SARS-CoV-2 in
293 companion animals, suggests that human infection preceded animal infection. In experimental infection
294 studies, viral RNA was detected up to the study endpoint-- 12 days post-infection for cats^{9,12,13}, while
295 only on day 6 for dogs⁹. However in cases of natural infection, viral RNA was detected up to 14 and 19
296 days in dogs⁶ and cats^{26,27}, respectively, post-confirmatory testing of the index patient. In this
297 investigation, the median time from symptom onset of the index patient to specimen collection was 27
298 days (range:3–46 days) and the median time from first positive diagnostic result of the index patient to
299 specimen collection was 20.5 days (range:3-42 days), which would have missed the shedding window
300 for infected pets and could explain the lack of viral RNA detection. The time to pet sampling from the
301 index patient's symptom onset and from diagnosis were similar among households with and without
302 seropositive pets, and therefore, most pets had a similar length of time to mount neutralizing antibody
303 responses since the beginning of their exposure to the household's human case(s). Additionally, the

304 sample size of enrolled and tested pets was insufficient to allow for definitive conclusions regarding risk
305 factors for pet infection and to compare interactions between pets and index patients.

306 Future investigations of household transmission should sample pets across the spectrum of exposure,
307 including time points closer to the start of the index patient's exposure window and at multiple
308 subsequent time points to learn more about viral shedding, symptomatology, and risk factors. Further
309 One Health efforts are needed to better understand the risk of SARS-CoV-2 transmission between
310 people and pets and to further characterize the course of SARS-CoV-2 infection in pets, both of which
311 will inform guidance and decision-making to best protect public health, animal health, and welfare.

312 This investigation shows that transmission of SARS-CoV-2 from people to pets can occur in household
313 settings. We identified a higher rate of seropositivity than previous studies. Given the relative frequency
314 of human-to-animal transmission in households with people with COVID-19, people with confirmed or
315 suspected COVID-19 should restrict contact with pets and other animals¹⁸. If a person must care for
316 their pet while they are sick, they should wear a mask and should wash their hands before and after
317 interacting with them¹⁸.

318 **Conclusions**

319 A One Health approach for the prevention and control of SARS-CoV-2^{2,28}, as well as other emerging
320 and zoonotic diseases, is critical, including response and surveillance efforts to capture and assess
321 transmission dynamics between people, animals, and their shared environment. Previous zoonotic and
322 infectious disease investigations have highlighted the importance of including pets in household
323 transmission investigations. Based on limited information available to date, the risk of pets spreading
324 COVID-19 to people appears low. This One Health investigation provides additional evidence that pets
325 can be infected with SARS-CoV-2, especially after contact with people with COVID-19. Pets contribute
326 to people's health and well-being, and proper prevention measures to limit microbial transmission
327 between people and pets should be taken to prevent zoonotic infections.

328 **Data Sharing**

329 Complete or near-complete genome sequences of SARS-CoV-2 obtained in this investigation are
330 available at Global Initiative on Sharing All Influenza Data (GISAID) and GenBank. Additional
331 information or de-identified data may be made available to researchers who submit a methodologically
332 sound proposal to the corresponding author.

333 **Acknowledgments**

334 The authors wish to thank members of the CDC COVID-19 One Health Working Group, CDC COVID-
335 19 Household Transmission Investigation Field Investigations Teams in Utah and Wisconsin, Drs. Aron
336 Hall, Scott Nabity, Jacqueline Tate, and others on the CDC COVID-19 Epidemiology Task Force.
337 Additionally, we would like to thank all our local, state, and federal human and animal health/laboratory
338 partners. We also thank Hannah Rettler and colleagues from the Utah Department of Health and Dr.
339 Stephen Welch for graphic design assistance with the figures. Lastly, a sincere thank you to the
340 participating households in the Salt Lake City and Milwaukee metropolitan areas for their interest in this
341 investigation and willingness to involve their pets, which made this One Health investigation possible.

342 **Disclaimers**

343 The findings and conclusions in this report are those of the authors and do not necessarily reflect the
344 official position of the Centers for Disease Control and Prevention or the institutions with which the
345 authors are affiliated.

346 References

- 347 1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.
348 *Nature medicine* 2020; **26**(4): 450-2.
- 349 2. El Zowalaty ME, Järhult JD. From SARS to COVID-19: A previously unknown SARS- related
350 coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. *One health*
351 (*Amsterdam, Netherlands*) 2020; **9**: 100124.
- 352 3. American Pet Products Association. 2019-2020 APPA National Pet Owners Survey. Stamford, CT:
353 American Pet Products Association, 2019.
- 354 4. Bowen J, García E, Darder P, Argüelles J, Fatjó J. The effects of the Spanish COVID-19 lockdown on
355 people, their pets, and the human-animal bond. *J Vet Behav* 2020; **40**: 75-91.
- 356 5. Duncan SL, Allen KJ, Hoa-atTf, practice gf. Service animals and their roles in enhancing independence,
357 quality of life, and employment for people with disabilities. 2000: 303-23.
- 358 6. Sit THC, Brackman CJ, Ip SM, et al. Infection of dogs with SARS-CoV-2. *Nature* 2020.
- 359 7. Zhang Q, Zhang H, Huang K, et al. SARS-CoV-2 neutralizing serum antibodies in cats: a serological
360 investigation. 2020: 2020.04.01.021196.
- 361 8. World Organisation for Animal Health. Events in animals. 2020. [https://www.oie.int/en/scientific-
362 expertise/specific-information-and-recommendations/questions-and-answers-on-2019-novel-coronavirus/events-
363 in-animals/](https://www.oie.int/en/scientific-expertise/specific-information-and-recommendations/questions-and-answers-on-2019-novel-coronavirus/events-in-animals/).
- 364 9. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to
365 SARS–coronavirus 2. 2020; **368**(6494): 1016-20.
- 366 10. Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of
367 Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis
368 and transmissibility. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*
369 *America* 2020.
- 370 11. Mykytyn AZ, Lamers MM, Okba NMA, et al. Susceptibility of rabbits to SARS-CoV-2. 2020:
371 2020.08.27.263988.
- 372 12. Bosco-Lauth AM, Hartwig AE, Porter SM, et al. Pathogenesis, transmission and response to re-exposure
373 of SARS-CoV-2 in domestic cats. 2020: 2020.05.28.120998.
- 374 13. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in Domestic Cats. 2020.
- 375 14. Kim YI, Kim SG, Kim SM, et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell host*
376 *& microbe* 2020; **27**(5): 704-9.e2.
- 377 15. Panamerican Health Organization. COVID-19 JOINT ANNOUNCEMENT ON THE NOVEL
378 CORONAVIRUS AND DOGS AND CATS 2020.
- 379 16. Huang Q, Zhan X, Zeng X-T. COVID-19 pandemic: stop panic abandonment of household pets. *Journal*
380 *of Travel Medicine* 2020; **27**(3).
- 381 17. Lewis NM, Chu VT, Ye D, et al. Household Transmission of SARS-CoV-2 in the United States. *Clinical*
382 *Infectious Diseases* 2020.
- 383 18. Centers for Disease Control and Prevention. What to Do If You Are Sick. 2020.
384 <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html>.
- 385 19. Wang L, Mitchell PK, Calle PP, et al. Complete Genome Sequence of SARS-CoV-2 in a Tiger from a
386 U.S. Zoological Collection. *Microbiol Resour Announc* 2020; **9**(22): e00468-20.
- 387 20. United States Department of Agriculture. Confirmed Cases of SARS-CoV-2 in Animals in the United
388 States. 2020. https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/sa_one_health/sars-cov-2-animals-us.
- 389 21. Temmam S, Barbarino A, Maso D, et al. Absence of SARS-CoV-2 infection in cats and dogs in close
390 contact with a cluster of COVID-19 patients in a veterinary campus. 2020: 2020.04.07.029090.
- 391 22. Patterson EI, Elia G, Grassi A, et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from
392 households in Italy. 2020: 2020.07.21.214346.
- 393 23. Barrs VR, Peiris M, Tam KWS, et al. SARS-CoV-2 in Quarantined Domestic Cats from COVID-19
394 Households or Close Contacts, Hong Kong, China. *Emerging infectious diseases* 2020; **26**(12).
- 395 24. Gaudreault NN, Trujillo JD, Carossino M, et al. SARS-CoV-2 infection, disease and transmission in
396 domestic cats. 2020: 2020.08.04.235002.

- 397 25. Centers for Disease Control and Prevention. If You Have Pets. 2020.
398 <https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/pets.html>.
399 26. Garigliany M, Van Laere AS, Clercx C, et al. SARS-CoV-2 Natural Transmission from Human to Cat,
400 Belgium, March 2020. *Emerging infectious diseases* 2020; **26**(12).
401 27. Newman A, Smith D, Ghai RR, et al. First Reported Cases of SARS-CoV-2 Infection in Companion
402 Animals - New York, March-April 2020. *MMWR Morbidity and mortality weekly report* 2020; **69**(23): 710-3.
403 28. Leroy EM, Ar Gouilh M, Brugère-Picoux J. The risk of SARS-CoV-2 transmission to pets and other wild
404 and domestic animals strongly mandates a one-health strategy to control the COVID-19 pandemic. *One health*
405 (*Amsterdam, Netherlands*) 2020: 100133-.
- 406

407 **Table 1. Characteristics of household pets enrolled in the One Health COVID-19 Household**
 408 **Transmission Investigation, April–May 2020**

Characteristics	Total N (column %)	Blood sample collected		No blood sample collected n (row %)
		Seropositive ¹ n (row %)	Seronegative n (row %)	
Total	56	8 (14)	39 (70)	9 (16)
Study site				
Utah	38 (68)	6 (16)	31 (82)	1 (3)
Wisconsin	18 (32)	2 (11)	8 (44)	8 (44)
Species				
Dog	37 (66)	4 (11)	30 (81)	3 (8)
Cat	19 (34)	4 (21)	9 (47)	6 (32)
Age (years)				
< 2	11 (20)	1 (9)	7 (64)	3 (27)
2–9	33 (59)	5 (15)	23 (70)	5 (15)
≥10	12 (21)	2 (17)	9 (75)	1 (8)
Sex and reproductive status				
Male	29 (52)	4 (14)	19 (66)	6 (21)
Neutered	23 (79)	3 (13)	16 (70)	4 (17)
Female	27 (48)	4 (15)	20 (74)	3 (11)
Spayed	22 (81)	4 (18)	15 (68)	3 (14)
Indoor/outdoor housing environment				
Primarily indoors	55 (98)	7 (13)	39 (71)	9 (16)
Primarily outdoors ²	1 (2)	1 (100)	0	0
Exposures outside of the household setting³				
Spent any time free-roaming in the yard or the neighborhood	29 (52)	5 (17)	21 (72)	3 (10)
Attended a social setting (e.g., dog park, daytime boarding facility, veterinary clinic)	5 (9)	0	5 (100)	0

409 ¹Serologic testing was conducted using a SARS-CoV-2 virus neutralization assay. Neutralizing titers
 410 greater than 16 were considered seropositive.

411 ²Defined as spending >50% time outdoors

412 ³Includes exposures documented after the household human index patient began isolation.

413

414 **Table 2: Characteristics of humans with SARS-CoV-2 infection, household members, and timing**
 415 **of human illness in households with pets enrolled in the One Health COVID-19 Household**
 416 **Transmission Investigation, April–May 2020**

Characteristic	Total households N=34	Households with ≥ 1 seropositive ¹ pet N=6	Households with seronegative pet(s) only N=24	Households with no pet blood sample collected N=4	p-value ²
Human SARS-CoV-2 infection and timing					
	Median (range)				
Proportion of human household members ³ with laboratory evidence of SARS-CoV-2 infection ⁴	0.45 (0.13–1.00)	0.79 (0.40–1.00)	0.37 (0.13–1.00)	0.63 (0.25–1.00)	0.01
Days from symptom onset in the human index patient to first date of pet sampling	27 (3–46)	28 (22–39)	24 (3–46)	32.5 (24–42)	0.30
Days from first positive diagnostic result of the human index patient to first date of pet sampling	20.5 (3–42)	21.5 (18–38)	20 (3–41)	25.5 (21–42)	0.37
Household members and size					
	Median (range)				
No. persons ⁵	4 (2–8)	4.5 (3–6)	4 (2–8)	3 (2–4)	0.70
No. dogs and cats ⁶	1 (1–5)	1.5 (1–3)	1 (1–5)	1 (1–2)	0.47
Total square meters	213.68 (55.74–706.06)	181.16 (90.95–315.87)	241.55 (55.74–706.06)	192.40 (130.06–260.13)	0.24

417 ¹Serologic testing was conducted using a SARS-CoV-2 virus neutralization assay. Neutralizing titers
 418 greater than 16 were considered seropositive.

419 ²Households with and without a seropositive pet by Mann-Whitney-Wilcoxon test.

420 ³Includes only household members enrolled in the COVID-19 Household Transmission Study; some
 421 household members declined participation.


422 ⁴Includes individuals positive on nasopharyngeal or nasal swabs by rRT-PCR or with SARS-CoV-2
 423 antibodies detected.

424 ⁵Includes all persons residing in the households, regardless of study enrollment.

425 ⁶Pets of other species were not assessed in this analysis.



426

427 **Figure 1. COVID-19 diagnostic testing and symptom duration among humans and animals in**
 428 **households with a seropositive pet, One Health COVID-19 Household Transmission Investigation,**
 429 **April–May 2020. Symptoms durations are shown only for humans. Pets with clinical signs are denoted**
 430 **with an *.**



431

432 **Figure 2. Timeline and phylogenetic analysis of human and dog testing in one household in Utah**
 433 **with SARS-CoV-2 RNA detected on the dog’s fur, One Health COVID-19 Household**
 434 **Transmission Investigation, April–May 2020.** Panel A. Timeline of human and dog testing in one
 435 household in Utah with six persons with laboratory-confirmed COVID-19 and SARS-CoV-2 RNA
 436 detected on the dog’s fur. The timeline indicates dates of reported symptoms and results of
 437 nasopharyngeal swab testing by rRT-PCR in human COVID-19 cases and samples collected from the
 438 dog in the household. Diagnostic samples* from the dog included oral, nasal, and rectal swabs and stool,
 439 which all tested negative by rRT-PCR, and a blood sample which was negative by virus neutralization.
 440 Panel B. Enhanced view of branch-tip from comprehensive phylogram (see Figure S2), depicting here
 441 the seven study sequences (red) alongside selected Utah complete genome sequences available
 442 from Global Initiative on Sharing All Influenza Data. Branch length is by divergence. See Figure S2 for
 443 zoomed-out dendrogram depicting additional available sequences from Utah.



444

445

Figure 3. (A) Reported duration of interaction per day and (B) types of interactions between human index patients and pets in each household before and after human index patient diagnosis, by pet serostatus – One Health COVID-19 Household Transmission Investigation, April–May 2020

